Unravelling the Vicious Cycle: Glucose Dysregulation and Inflammatory Mediators in Concurrent RA and T2D

1 Introduction#

Rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2D) rank among the most prevalent chronic diseases worldwide, each imposing a substantial individual and societal burden. RA is a systemic autoimmune disorder characterised by persistent synovial inflammation, progressive joint destruction, and extra-articular manifestations that can involve the cardiovascular, pulmonary, and metabolic systems. Affecting approximately 0.5–1 % of the global population, RA predominantly strikes women in middle age and remains a leading cause of disability when inadequately controlled. Type 2 diabetes, by contrast, is a progressive metabolic disease defined by insulin resistance and relative insulin deficiency, resulting in chronic hyperglycaemia. Its prevalence continues to rise in parallel with increasing rates of obesity and sedentary lifestyles, currently affecting more than 500 million adults worldwide and projecting further escalation in the coming decades.

Although traditionally regarded as distinct clinical entities— one primarily inflammatory and the other metabolic— accumulating epidemiological and mechanistic evidence reveals a striking bidirectional association between RA and T2D. Patients with RA exhibit an approximately 1.5-fold higher risk of developing T2D compared with the general population, with prevalence estimates reaching nearly 15 % in several cohorts. Conversely, the presence of T2D appears to influence the course and treatment response of RA. This reciprocal relationship is not merely coincidental; rather, it is underpinned by a self-reinforcing “vicious cycle” in which chronic systemic inflammation and glucose dysregulation continuously amplify one another. Pro-inflammatory cytokines that drive synovial inflammation and joint damage simultaneously impair insulin signalling, promote β-cell dysfunction, and foster insulin resistance. In turn, hyperglycaemia and the attendant metabolic stress further activate inflammatory pathways, thereby exacerbating RA disease activity and increasing cardiovascular risk—the leading cause of mortality in both conditions.

Recognition of this interconnected pathophysiology has important clinical implications. Conventional management strategies that treat RA and T2D as separate entities may overlook opportunities for dual therapeutic benefit. Targeted inhibition of key inflammatory mediators, for example, has been shown in selected studies not only to control joint inflammation but also to improve glycaemic parameters. Conversely, suboptimal control of either disease can undermine outcomes in the other. Despite growing awareness of the comorbidity, the precise molecular links that sustain the vicious cycle, the relative contributions of individual cytokines, and the differential metabolic effects of current RA therapies remain incompletely elucidated.

The purpose of this review is therefore to dissect the shared inflammatory and metabolic pathways that link glucose dysregulation with RA pathogenesis. By synthesising current epidemiological, experimental, and clinical evidence, we aim to clarify how chronic inflammation drives insulin resistance and β-cell impairment, and how glucose dysregulation in turn perpetuates the inflammatory cascade. The article is structured as follows: Section 2 summarises the epidemiology of concurrent RA and T2D; Section 3 examines the core pathophysiological mechanisms; Section 4 details the self-perpetuating vicious cycle; Section 5 focuses on the principal inflammatory mediators and their metabolic consequences; Section 6 evaluates the therapeutic implications of breaking the cycle with existing and emerging RA treatments; Section 7 outlines practical clinical management recommendations; and Section 8 identifies key research gaps and future directions. Through this systematic exploration, we seek to provide a coherent framework that can guide both scientific inquiry and integrated clinical care for patients affected by both diseases.

2 Epidemiology of Concurrent RA and T2D#

The coexistence of rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2D) is now well documented and represents a clinically significant comorbidity. Multiple observational studies and meta-analyses consistently demonstrate that individuals with RA carry an elevated risk of developing T2D compared with the general population. Pooled estimates indicate an approximately 1.5-fold higher risk, corresponding to a relative increase of roughly 23–50 % depending on the study design and comparator group.

Incidence rates of new-onset T2D among patients with RA also exceed those observed in non-RA cohorts. Large population-based studies report crude incidence rates in the range of 7–12 cases per 1,000 person-years, with higher rates noted in older patients and those with longer disease duration. Several factors modulate this elevated risk. Advancing age and higher body-mass index (BMI) remain the strongest conventional predictors, mirroring patterns seen in the general population. In the RA-specific context, additional contributors include prolonged disease duration, high cumulative inflammatory burden (reflected by persistently elevated C-reactive protein or disease-activity scores), physical inactivity secondary to joint pain and functional limitation, and—most notably— exposure to systemic glucocorticoids. Glucocorticoid use shows a clear dose- and duration-dependent association with incident T2D; even low-to-moderate daily doses, when continued over months to years, measurably increase risk. Conversely, certain conventional and biologic disease-modifying antirheumatic drugs (DMARDs) appear neutral or modestly protective, although residual confounding by indication complicates interpretation.

The dual diagnosis of RA and T2D carries substantial implications for morbidity and mortality. Both conditions independently accelerate atherosclerosis through overlapping mechanisms of chronic inflammation, endothelial dysfunction, and metabolic stress. Their coexistence therefore amplifies cardiovascular risk beyond that attributable to either disease alone. Patients with concurrent RA and T2D experience higher rates of myocardial infarction, stroke, heart failure, and cardiovascular mortality. Beyond cardiovascular endpoints, the combination is associated with increased overall hospitalisation rates, accelerated functional decline, higher healthcare utilisation, and reduced quality of life. Excess mortality observed in RA cohorts is partly mediated by this metabolic comorbidity, underscoring the clinical urgency of early recognition and integrated management.

Key epidemiological evidence derives from several high-quality sources. Meta-analyses of cohort and case-control studies have quantified the excess T2D risk in RA and confirmed the contribution of inflammatory activity and glucocorticoid exposure. Large administrative-database analyses (including claims-based and registry studies from North America, Europe, and Asia) have provided robust incidence estimates and have begun to disentangle the differential effects of individual DMARD classes. Prospective cohort studies with detailed phenotype data have further linked higher disease-activity scores and lower physical-function measures to subsequent diabetes onset. Collectively, these investigations establish that the elevated occurrence of T2D in RA is both real and clinically consequential, driven by a combination of traditional metabolic risk factors and disease-specific inflammatory and treatment-related influences.

In summary, the epidemiology of concurrent RA and T2D reveals a consistent excess burden that translates into heightened cardiovascular and overall morbidity. Accurate characterisation of prevalence, incidence, and modifiable risk factors forms the necessary foundation for understanding the underlying pathophysiological cycle and for designing targeted preventive and therapeutic strategies.

3 Shared Pathophysiological Mechanisms#

At the core of the association between rheumatoid arthritis (RA) and type 2 diabetes (T2D) lies chronic systemic inflammation, which serves as the principal pathogenic driver linking joint pathology with metabolic dysregulation. In RA, persistent activation of the innate and adaptive immune systems generates a sustained pro-inflammatory milieu that extends far beyond the synovium. Circulating and tissue levels of key cytokines—tumour necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6)—are markedly elevated. These same mediators orchestrate synovial hyperplasia, cartilage degradation, and bone erosion while simultaneously exerting profound effects on insulin-sensitive tissues and pancreatic β-cells, thereby establishing the molecular foundation for the observed comorbidity.

TNF-α, IL-1, and IL-6 contribute to joint destruction through well-characterised pathways: they stimulate production of matrix metalloproteinases, activate osteoclasts via RANKL induction, and perpetuate leukocyte recruitment into the synovium. Concurrently, these cytokines disrupt metabolic homeostasis. TNF-α and IL-6 promote insulin resistance in skeletal muscle, adipose tissue, and liver, while IL-1 exerts particularly detrimental effects on pancreatic β-cell survival and function. The dual actions of these mediators illustrate how a single inflammatory cascade can drive both articular damage and glucose dysregulation.

Insulin resistance in patients with RA arises through several interlocking mechanisms. At the cellular level, pro-inflammatory cytokines interfere with insulin-receptor signalling. TNF-α and IL-6 induce serine phosphorylation of insulin-receptor substrate-1 (IRS-1), which impairs its tyrosine phosphorylation and subsequent downstream activation of the phosphoinositide-3-kinase/Akt pathway. Consequently, translocation of glucose transporter type 4 (GLUT4) to the cell membrane is reduced, diminishing insulin-stimulated glucose uptake in muscle and adipose tissue. In addition, chronic inflammation alters the adipokine profile: circulating concentrations of leptin and resistin—both of which favour insulin resistance—are typically elevated, whereas levels of the insulin-sensitising adipokine adiponectin are reduced. This adipokine imbalance further amplifies systemic insulin resistance and contributes to ectopic lipid accumulation and hepatic steatosis.

Beyond peripheral insulin resistance, inflammatory cytokines directly compromise pancreatic β-cell function and viability. IL-1β, in particular, induces β-cell stress through activation of the nuclear factor-κB (NF-κB) and mitogen-activated protein kinase pathways, leading to increased expression of pro-apoptotic proteins and impaired insulin gene transcription. Prolonged exposure results in β-cell apoptosis and progressive loss of insulin secretory capacity. Experimental models and clinical observations confirm that this cytokine-mediated β-cell injury is exaggerated in the context of RA, where systemic IL-1 and related mediators remain chronically elevated.

Importantly, the relationship is bidirectional: glucose dysregulation itself feeds back into and intensifies the inflammatory state. Hyperglycaemia and the associated increase in advanced glycation end-products activate NF-κB and other transcription factors in immune cells, endothelial cells, and synoviocytes. This amplifies production of TNF-α, IL-1, and IL-6, thereby closing the loop and perpetuating both joint inflammation and metabolic disturbance. Oxidative stress and mitochondrial dysfunction, secondary to chronic hyperglycaemia, further reinforce this feed-forward cycle.

Collectively, these shared mechanisms—cytokine-driven interference with insulin signalling, adipokine imbalance, β-cell dysfunction, and the reciprocal amplification of inflammation by hyperglycaemia—provide a coherent biological explanation for the frequent coexistence of RA and T2D. Understanding these pathways is essential for identifying therapeutic targets capable of interrupting the cycle at multiple points.

4 The Vicious Cycle in Detail#

The bidirectional relationship between rheumatoid arthritis (RA) and type 2 diabetes (T2D) operates as a self-reinforcing vicious cycle in which chronic inflammation and glucose dysregulation continuously amplify each other. Understanding the sequential steps of this loop, together with the factors that sustain it, is essential for identifying points of therapeutic intervention.

The cycle is typically initiated by the persistent systemic inflammation of active RA. Elevated levels of pro-inflammatory cytokines—particularly TNF-α, IL-1, and IL-6— impair insulin signalling in peripheral tissues through serine phosphorylation of insulin-receptor substrate-1 (IRS-1) and reduced translocation of GLUT4. At the same time, these cytokines induce endoplasmic-reticulum stress and apoptosis in pancreatic β-cells, diminishing insulin secretory capacity. The combined effect is progressive insulin resistance, rising plasma glucose, and eventual hyperglycaemia.

Once hyperglycaemia is established, metabolic stress feeds back into the inflammatory cascade. Elevated glucose concentrations accelerate the formation of advanced glycation end-products, increase generation of reactive oxygen species, and activate the transcription factor NF-κB in immune cells, endothelial cells, and resident synoviocytes. This leads to further production of TNF-α, IL-1, and IL-6, intensifying both synovial inflammation and systemic inflammatory tone. The result is worsened RA disease activity, accelerated joint damage, and further deterioration of metabolic control— completing and perpetuating the loop.

Several additional factors act as accelerators within this cycle. Systemic glucocorticoid therapy, commonly used for disease flares or as bridging treatment, directly promotes hepatic gluconeogenesis, reduces peripheral insulin sensitivity, and can precipitate or exacerbate hyperglycaemia in a clear dose- and duration-dependent manner. Physical inactivity, driven by joint pain, stiffness, and functional limitation, decreases insulin-stimulated glucose uptake, favours accumulation of visceral adipose tissue, and elevates baseline inflammatory markers. Alterations in the gut microbiome, increasingly recognised in both RA and T2D, may increase intestinal permeability and translocation of microbial products that stimulate innate immune responses, thereby reinforcing systemic inflammation and insulin resistance. Chronic oxidative stress, generated by both persistent cytokine activity and hyperglycaemia, serves as a central amplifier: it damages cellular macromolecules, sustains NF-κB activation, and further impairs β-cell function and insulin signalling.

In summary, the vicious cycle linking RA and T2D is driven by reciprocal amplification of inflammation and glucose dysregulation and is reinforced by glucocorticoid use, reduced physical activity, microbiome alterations, and oxidative stress. Effective interruption of any major node of this loop holds the potential to improve both articular and metabolic outcomes simultaneously.

5 Key Inflammatory Mediators and Their Metabolic Effects#

Among the numerous inflammatory mediators elevated in rheumatoid arthritis (RA), three cytokines—tumour necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6)— stand out for their dual roles in driving joint destruction and disrupting glucose homeostasis. A detailed examination of their pathways and the supporting experimental and clinical evidence clarifies how each contributes to the metabolic disturbances observed in concurrent RA and type 2 diabetes (T2D).

TNF-α is one of the earliest and most extensively studied cytokines in both RA and metabolic disease. In the synovium it promotes leukocyte recruitment, angiogenesis, and production of matrix-degrading enzymes. Systemically, TNF-α induces insulin resistance primarily by stimulating serine phosphorylation of insulin-receptor substrate-1 (IRS-1), thereby impairing downstream phosphoinositide-3-kinase/ Akt signalling and reducing GLUT4-mediated glucose uptake in skeletal muscle and adipose tissue. Experimental studies in animal models of obesity and diabetes have shown that neutralisation of TNF-α improves insulin sensitivity and lowers ambient glucose levels. Clinical observations in patients with RA treated with TNF inhibitors have reported favourable changes in insulin-resistance indices (HOMA-IR) and, in some cohorts, a reduced incidence of new-onset T2D, supporting a causal contribution of this cytokine to glucose dysregulation.

IL-1, particularly the IL-1β isoform, exerts potent effects on both the joint and the pancreatic islet. Within the synovium it amplifies inflammation and cartilage catabolism. In β-cells, IL-1β activates NF-κB and mitogen-activated protein kinase pathways, leading to increased expression of pro-apoptotic proteins, impaired insulin-gene transcription, and eventual β-cell death. Experimental work has demonstrated that IL-1 receptor antagonism protects islets from cytokine-mediated damage and preserves insulin secretion. Clinical evidence is particularly compelling: randomised trials of the IL-1 receptor antagonist anakinra in patients with RA and comorbid T2D have shown significant reductions in HbA1c that exceed those observed with TNF inhibition alone, alongside concurrent improvement in RA disease activity. These findings indicate that IL-1 is a critical mediator of β-cell dysfunction in the setting of chronic inflammation.

IL-6 occupies a more complex position. It is a major driver of the acute-phase response and contributes to synovial inflammation and osteoclast activation in RA. Metabolically, IL-6 can exert both acute insulin-sensitising effects (via AMPK activation during exercise) and chronic insulin-resistance– promoting effects when persistently elevated. In the context of RA, sustained high IL-6 levels correlate with increased hepatic glucose production and peripheral insulin resistance. Clinical studies of IL-6 receptor blockade (tocilizumab or sarilumab) have documented improvements in insulin-sensitivity markers and modest reductions in HbA1c among patients with RA, including those with pre-existing diabetes. Post-hoc analyses of large trial datasets further suggest that IL-6 inhibition may offer greater glycaemic benefit than TNF inhibition in certain patient subgroups.

Beyond these three principal cytokines, several emerging mediators warrant brief consideration. Interleukin-17 (IL-17) and interleukin-18 have been implicated in both synovial inflammation and experimental models of insulin resistance. Chemokines such as CCL2 (MCP-1) facilitate adipose-tissue macrophage infiltration, thereby linking local inflammation to systemic metabolic disturbance. Members of the IL-12/IL-23 family and certain adipokines regulated by inflammatory signals also participate in the broader network, although their precise contributions to glucose homeostasis in RA remain less well quantified than those of TNF-α, IL-1, and IL-6.

Taken together, the experimental and clinical evidence establishes TNF-α, IL-1, and IL-6 as central molecular links between articular inflammation and disordered glucose metabolism. Their overlapping yet distinct effects on insulin signalling and β-cell integrity explain why targeted inhibition of these pathways can simultaneously ameliorate RA disease activity and improve metabolic parameters, offering a rational basis for therapeutic strategies aimed at interrupting the vicious cycle.

6 Therapeutic Implications: Breaking the Cycle#

Recognition of the vicious cycle linking rheumatoid arthritis (RA) and type 2 diabetes (T2D) carries direct therapeutic consequences. Different classes of RA medications exert markedly divergent effects on glucose homeostasis, ranging from clear deterioration to meaningful improvement. Understanding these differential metabolic actions allows clinicians to select treatments that simultaneously control joint inflammation and favourably influence insulin sensitivity and glycaemic parameters.

Systemic glucocorticoids remain the agents most consistently associated with worsened glycaemic control. Through promotion of hepatic gluconeogenesis, reduction of peripheral insulin sensitivity, and impairment of β-cell function, glucocorticoids elevate blood glucose in a dose- and duration-dependent manner. Even relatively low daily doses, when continued over prolonged periods, increase the incidence of new-onset T2D and destabilise existing diabetes. Consequently, minimising cumulative glucocorticoid exposure constitutes a fundamental principle in the management of patients with concurrent RA and T2D.

In contrast, several conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) demonstrate neutral or protective metabolic effects. Hydroxychloroquine has the strongest evidence base: multiple observational studies and meta-analyses show a significant reduction in the risk of incident T2D, together with modest improvements in fasting glucose and HbA1c among patients already diagnosed with diabetes. Methotrexate is associated with a lower incidence of new-onset diabetes compared with non-users or glucocorticoid-treated patients, an effect attributed both to better overall disease control and to possible direct anti-inflammatory actions on insulin-sensitive tissues. These favourable profiles support the preferential use of hydroxychloroquine and methotrexate, alone or in combination, in patients at elevated metabolic risk.

Biologic and targeted synthetic DMARDs offer the most compelling opportunities for dual benefit. TNF inhibitors improve insulin-resistance indices (HOMA-IR) in several clinical series and have been linked to a reduced incidence of T2D in large cohort studies. IL-1 blockade with anakinra has produced particularly striking results: randomised trials in patients with RA and comorbid T2D demonstrated significant reductions in HbA1c that exceeded those achieved with TNF inhibition, concurrent with equivalent control of RA disease activity. IL-6 receptor antagonists (tocilizumab, sarilumab) similarly improve insulin sensitivity and lower HbA1c in post-hoc analyses of clinical trial data. More recently, Janus kinase (JAK) inhibitors, exemplified by tofacitinib, have shown progressive reductions in HOMA-IR and trends toward improved HbA1c alongside robust suppression of RA disease activity, suggesting that interruption of JAK/STAT signalling can simultaneously address both inflammatory and metabolic components of the cycle.

Collectively, these findings establish that targeted inhibition of key cytokines or downstream signalling pathways can yield concurrent improvements in RA disease activity scores and metabolic markers such as HbA1c and HOMA-IR. The magnitude of glycaemic benefit appears greatest when the chosen agent directly addresses mediators most closely linked to β-cell dysfunction and insulin resistance (IL-1 and, to a somewhat lesser extent, IL-6 and JAK pathways).

Practical treatment selection in patients with both conditions should therefore integrate rheumatological and metabolic considerations. First-line therapy preferably includes methotrexate with or without hydroxychloroquine, while systemic glucocorticoids are used at the lowest effective dose for the shortest duration. When escalation to advanced therapies is required, agents with documented metabolic advantages—IL-1 inhibitors, IL-6 inhibitors, selected TNF inhibitors, or JAK inhibitors—merit preferential consideration, particularly in patients with inadequate glycaemic control or high cardiovascular risk. Close collaboration between rheumatologists and endocrinologists, together with regular monitoring of HbA1c, fasting glucose, and insulin-resistance indices after treatment changes, enables timely adjustment and maximises the potential to interrupt the vicious cycle at both its inflammatory and metabolic nodes.

7 Clinical Management Recommendations#

Effective management of patients with concurrent rheumatoid arthritis (RA) and type 2 diabetes (T2D), or those at elevated risk of developing T2D, requires proactive strategies that address both the inflammatory and metabolic dimensions of the vicious cycle. The following recommendations synthesise current evidence into practical clinical guidance.

7.1 Screening strategies for T2D in RA patients#

Given the approximately 1.5-fold increased risk of T2D, systematic screening should form part of routine RA care. Baseline assessment at the time of RA diagnosis (or at the first specialist encounter) should include fasting plasma glucose, HbA1c, and, where resources permit, a measure of insulin resistance such as HOMA-IR. Thereafter, screening intervals of 12 months are appropriate for most patients; more frequent testing (every 6 months) is warranted in those with additional risk factors, including age >50 years, obesity (BMI ≥30 kg/m²), long-standing or high-disease-activity RA, current or recent glucocorticoid use, and family history of diabetes. Opportunistic testing during hospital admissions or flares is also advisable. Early detection allows timely lifestyle intervention and informs the choice of RA therapy before irreversible β-cell loss occurs.

7.2 Monitoring glycaemic parameters during RA therapy changes#

Any substantial alteration in RA treatment—particularly initiation, escalation, or tapering of glucocorticoids, or introduction of a biologic or targeted synthetic DMARD— should prompt intensified glycaemic surveillance. HbA1c and fasting glucose should be rechecked within 8–12 weeks of the change. In patients already diagnosed with T2D, more frequent self-monitoring of blood glucose or continuous glucose monitoring may be required during glucocorticoid courses. Clinicians should remain alert to both deterioration (especially with glucocorticoids) and unexpected improvement (with hydroxychloroquine, IL-1/IL-6 inhibitors, or JAK inhibitors), adjusting antidiabetic regimens accordingly to avoid hypoglycaemia.

7.3 Integrated multidisciplinary approach#

Optimal care is best delivered through coordinated collaboration between rheumatology and endocrinology, supplemented by structured lifestyle intervention. Joint clinics or shared-care protocols facilitate simultaneous optimisation of disease-modifying therapy and glycaemic control. Lifestyle measures—regular physical activity tailored to joint limitations, modest weight reduction, and dietary patterns that favour insulin sensitivity—remain foundational and can amplify the metabolic benefits of anti-inflammatory drugs. Patient education that emphasises the bidirectional nature of the two conditions improves adherence and empowers self-management. Involvement of specialist nurses, dietitians, and physiotherapists further strengthens the care continuum.

7.4 Gaps in current guidelines and opportunities for personalised medicine#

Existing RA and diabetes guidelines largely address each disease in isolation and provide limited guidance on comorbidity-specific treatment selection or monitoring intensity. There is a clear need for consensus recommendations that incorporate metabolic risk into RA treatment algorithms and, conversely, that consider inflammatory burden when selecting antidiabetic agents. Opportunities for personalised medicine include the use of baseline cytokine profiles, genetic markers of insulin resistance, or simple clinical scores that integrate disease activity with metabolic risk to guide choice of biologic or targeted synthetic DMARD. Prospective studies evaluating such stratified approaches, together with the incorporation of metabolic endpoints into future RA trials, will be essential to move from reactive to truly anticipatory care.

In summary, systematic screening, vigilant monitoring around treatment transitions, multidisciplinary collaboration, and the progressive adoption of personalised strategies constitute the practical framework for interrupting the RA–T2D cycle and improving long-term outcomes.

8 Future Directions and Research Needs#

Despite substantial progress in delineating the inflammatory and metabolic links between rheumatoid arthritis (RA) and type 2 diabetes (T2D), critical knowledge gaps remain. Addressing these gaps will require coordinated research efforts spanning epidemiology, clinical trials, pharmacology, and systems biology.

Large prospective cohort studies and adequately powered randomised controlled trials that incorporate metabolic endpoints as pre-specified outcomes are urgently needed. Most existing evidence on the glycaemic effects of RA therapies derives from observational analyses, post-hoc evaluations, or small proof-of-concept studies. Future trials of conventional, biologic, and targeted synthetic DMARDs should systematically assess changes in HbA1c, fasting glucose, HOMA-IR, and incident diabetes, ideally with sufficient follow-up to capture both short-term and sustained metabolic effects. Head-to-head comparisons among cytokine inhibitors and JAK inhibitors, stratified by baseline metabolic risk, would further clarify which agents offer the greatest dual benefit.

The development of novel dual-action agents and the strategic repurposing of existing drugs represent promising avenues. Molecules designed to simultaneously inhibit key inflammatory pathways (for example, IL-1 or JAK/STAT) and improve insulin signalling could interrupt the vicious cycle more efficiently than current single-target therapies. Conversely, certain antidiabetic agents—particularly metformin, SGLT2 inhibitors, and GLP-1 receptor agonists— possess anti-inflammatory properties that merit formal evaluation in RA populations, both for potential disease-modifying effects and for cardiovascular-renal protection in patients with dual diagnoses.

Advanced biomarkers and multi-omics approaches hold considerable potential for predicting individual susceptibility to the cycle and for monitoring its interruption. Integration of circulating cytokine panels, adipokine profiles, metabolomics, proteomics, and transcriptomic signatures from blood or synovial tissue may enable earlier identification of patients at highest risk of metabolic deterioration. Such signatures could also serve as intermediate endpoints in early-phase trials and support the development of personalised treatment algorithms that match specific inflammatory drivers with the most metabolically favourable therapy.

Several fundamental questions remain unanswered. The extent to which the observed association is truly causal versus driven by shared risk factors or residual confounding continues to warrant rigorous investigation, including Mendelian-randomisation studies and analyses of untreated or undertreated RA cohorts. The long-term metabolic sequelae of prolonged exposure to modern biologics and JAK inhibitors—beyond the relatively short horizons of existing studies—are incompletely characterised. Additional uncertainties include the precise contribution of the gut microbiome, the impact of residual subclinical inflammation on insulin resistance after clinical remission is achieved, and the optimal sequencing or combination of anti-inflammatory and antidiabetic therapies.

By systematically addressing these research priorities, the field can move from descriptive understanding of the RA–T2D cycle toward predictive, preventive, and precisely targeted interventions that improve both articular and metabolic outcomes.

9 Conclusions#

Rheumatoid arthritis (RA) and type 2 diabetes (T2D) are linked by a self-reinforcing vicious cycle in which chronic systemic inflammation and glucose dysregulation continuously amplify one another. Pro-inflammatory cytokines that drive synovial inflammation and joint damage simultaneously impair insulin signalling, promote β-cell dysfunction, and foster insulin resistance. In turn, hyperglycaemia and the attendant metabolic stress further activate inflammatory pathways, thereby exacerbating RA disease activity and elevating cardiovascular risk. This bidirectional relationship is reinforced by glucocorticoid exposure, physical inactivity, oxidative stress, and other clinical and biological factors.

Recognition of this interconnected pathophysiology carries clear clinical importance. Treating either condition in isolation risks incomplete control of the other and may allow the cycle to progress unchecked. Systematic screening for T2D in patients with RA, vigilant monitoring of glycaemic parameters around changes in anti-rheumatic therapy, and preferential selection of agents with favourable metabolic profiles— particularly hydroxychloroquine, selected cytokine inhibitors, and JAK inhibitors—offer practical means of interrupting the loop. Minimising cumulative glucocorticoid use remains a cornerstone of metabolic protection.

Ultimately, improved outcomes for patients affected by both diseases will depend on integrated therapeutic strategies that simultaneously target inflammatory and metabolic drivers. Multidisciplinary collaboration between rheumatology and endocrinology, incorporation of lifestyle intervention, and the progressive adoption of personalised approaches based on individual inflammatory and metabolic phenotypes are essential. By addressing the vicious cycle as a unified clinical entity rather than two parallel comorbidities, clinicians and researchers can reduce the substantial morbidity and mortality associated with concurrent RA and T2D and move toward more effective, holistic care.